Any current/future new fundraising through debt or equity?

For the Rs. 750 crores CAPEX on the BSC Unit II expansion: - The first phase (Rs. 300-400 crores) will be funded 99% through internal accruals. - For the second phase, depending on first phase operations, the company may need Rs. 50-100 crores debt borrowing. Regarding IPO plans: - No specific updates were provided other than that the company had planned an IPO earlier. Overall, no immediate large-scale equity fundraising mentioned; minor debt could be used for the second CAPEX phase.

Any current/future capex/capital investment/strategic investment?

Ongoing CAPEX of Rs. 750 crores for Balaji Specialty Chemicals (BSC) Unit II, split into two phases (Rs. 300-400 crores first phase, Rs. 350 crores second phase), targeting products like sodium cyanide, triethyl orthoformate, EDTA derivatives, and others. Methylamines plant expansion of 40,000 tons capacity, expected to be commissioned by December 2024. New plant for Electronic grade Dimethyl Carbonate (DMC) with 15,000 MT per annum capacity, targeting the India EV battery market, commissioning in FY24-25. Dimethyl ether (DME) manufacturing project at Unit IV, expected launch by March 2025. Pr

Future growth expectations in sales/revenue/volumes?

The company anticipates significant growth and favorable market conditions in FY 2024-25. Standalone volume growth is guided at a minimum of 10% conservatively, excluding expansions. Demand improvement observed with 8.25% volume growth year-on-year; expected to continue improving in coming quarters. Capacity expansions (e.g., methylamine plant, specialty chemicals unit) will support volume and revenue growth. New phases of CAPEX (total ~Rs. 750 crores) aimed at specialty chemicals expected to increase revenues substantially. Solar power plant and captive power initiatives will improve cost eff

Future growth expectations in earnings/operating earnings/profits/EPS?

Management anticipates minimum standalone volume growth of 10% for FY '25, conservatively. EBITDA margins are expected to range between 21% to 24% going forward. Specialty Chemicals and amines derivatives expansions (e.g., new methylamine and dimethyl ether plants) should bolster growth. New product launches and capacity expansions (e.g., BSC Unit II with Rs. 750 crore CAPEX) are set to drive incremental revenues, estimated to cross INR 1,000 crores from Unit II alone. Increased captive consumption through expansions (e.g., methylamines) will improve margins and profitability. Solar power plan

Balaji AminesQ4 FY24Chemicals & Petrochemicals

Balaji Amines Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,848.8P/E: 29.3Market Cap: ₹6.0K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Order

N/A

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

The company anticipates significant growth and favorable market conditions in FY 2024-25.
Standalone volume growth is guided at a minimum of 10% conservatively, excluding expansions.
Demand improvement observed with 8.25% volume growth year-on-year; expected to continue improving in coming quarters.
Capacity expansions (e.g., methylamine plant, specialty chemicals unit) will support volume and revenue growth.
New phases of CAPEX (total ~Rs. 750 crores) aimed at specialty chemicals expected to increase revenues substantially.
Solar power plant and captive power initiatives will improve cost efficiency and sustainability.
Specialty chemicals volume recovery is expected alongside sustained demand in amines and derivatives.
Improved utilization of DMF and methylamine plants will boost production and exports.
FY 2024-25 outlook is optimistic, targeting sustained revenue and volume growth backed by new capacities and market recovery.

Margin guidance

Category 3

Management anticipates minimum standalone volume growth of 10% for FY '25, conservatively.
EBITDA margins are expected to range between 21% to 24% going forward.
Specialty Chemicals and amines derivatives expansions (e.g., new methylamine and dimethyl ether plants) should bolster growth.
New product launches and capacity expansions (e.g., BSC Unit II with Rs. 750 crore CAPEX) are set to drive incremental revenues, estimated to cross INR 1,000 crores from Unit II alone.
Increased captive consumption through expansions (e.g., methylamines) will improve margins and profitability.
Solar power plant commissioning by year-end aims to reduce power costs and carbon footprint, aiding cost-efficient operations.
The company remains debt-free, enabling financial stability for sustainable growth.
Overall, management expresses confidence in sustained growth, improved margins, and higher EPS buoyed by capacity additions and favorable market conditions.

See what Balaji Amines management said on margin guidance — free account, 30 seconds.

Fundraise plans

For the Rs. 750 crores CAPEX on the BSC Unit II expansion:
- The first phase (Rs. 300-400 crores) will be funded 99% through internal accruals.
- For the second phase, depending on first phase operations, the company may need Rs. 50-100 crores debt borrowing.
Regarding IPO plans:
- No specific updates were provided other than that the company had planned an IPO earlier.
Overall, no immediate large-scale equity fundraising mentioned; minor debt could be used for the second CAPEX phase.

Order book

The transcript provided does not explicitly mention the current or expected order book or pending orders for Balaji Amines Limited. However, some relevant insights include: - The company foresees a period marked by significant growth and favorable market conditions in FY 2024-25. - Volume growth guidance is a minimum of 10% on a standalone basis, indicating healthy demand outlook. - Expansion plans such as the new methylamine plant commissioning in December 2024 and specialty chemicals capacity addition suggest anticipated orders. - Investment of Rs. 750 crores in subsidiary (BSC Unit II) with expected minimum Rs. 1,000 crores revenue from the new unit implies a strong order pipeline. - Solar power plant and captive power initiatives will support operational efficiencies underlying growth in orders. - Management expressed optimism regarding promising market opportunities and sustained growth. No precise quantitative or formal order book data was disclosed in the call transcript.

See what Balaji Amines management said on order book — free account, 30 seconds.

Capex plans

Yes

Ongoing CAPEX of Rs. 750 crores for Balaji Specialty Chemicals (BSC) Unit II, split into two phases (Rs. 300-400 crores first phase, Rs. 350 crores second phase), targeting products like sodium cyanide, triethyl orthoformate, EDTA derivatives, and others.
Methylamines plant expansion of 40,000 tons capacity, expected to be commissioned by December 2024.
New plant for Electronic grade Dimethyl Carbonate (DMC) with 15,000 MT per annum capacity, targeting the India EV battery market, commissioning in FY24-25.
Dimethyl ether (DME) manufacturing project at Unit IV, expected launch by March 2025.
Proposed plants for N-Methyl Morpholine (3,000 TPA), N-(n-butyl) Thiophosphoric Triamide (NBPT, 2,500 TPA), and isopropylamine (modification of existing Ethylamine plant).
New 20 MW solar power plant at Solapur, Maharashtra; phase 1 with 8 MW expected operational by December 2024, aiming for up to 100% power from solar post expansions.
Hotel expansion with 40 additional rooms costing Rs. 30-35 crores.

Track Balaji Amines — get its next earnings analysis in your feed

How does Balaji Amines rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisBalaji Amines

Rev 3Mar 3

See where Balaji Amines sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Balaji Amines rank in Chemicals & Petrochemicals?

Compare Balaji Amines against every Chemicals & Petrochemicals company (Q4 FY24) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Balaji Amines's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Alufluoride Ltd (Q1 FY27)
Revenue from operations for Q1 FY27 was ₹26.6 crore, down 39% YoY (Page 6, 7, 8). Key investor presentation takeaways from Alufluoride Ltd's Q1 FY27 investor pr
POCL Enterprises Ltd (Q1 FY27)
466.03 crores (Page 12, 17, 11) . Key investor presentation takeaways from POCL Enterprises Ltd's Q1 FY27 investor presentation — and how it ranks against secto
Deepak Nitrite Ltd (Q2 FY27)
Q2 FY27 total revenue: ₹3,091 crore, up 61% YoY (Page 1, 4, 5, 6, 10, 11) . Key investor presentation takeaways from Deepak Nitrite Ltd's Q2 FY27 investor prese
Privi Speciality Chemicals Ltd (Q2 FY27)
19,239.47 lakhs (approximately 33.9% growth). Key results statement takeaways from Privi Speciality Chemicals Ltd's Q2 FY27 results statement — and how it ranks

Compare:vs Solar Industries vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Balaji Amines Q4 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Balaji Amines rank in Chemicals & Petrochemicals?

Continue your research

What Balaji Amines's management said in earlier quarters

Others in Chemicals & Petrochemicals this season